---
title: "BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 | BCDA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295003295.md"
description: "BioCardia, Inc. (NASDAQ: BCDA) announced it will host a conference call on August 12, 2026, at 4:30 PM EDT to report its Q2 2026 financial results and provide a corporate update. The event includes management remarks and a Q&A session, accessible via phone, live webcast, and replays."
datetime: "2026-08-05T11:16:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295003295.md)
  - [en](https://longbridge.com/en/news/295003295.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295003295.md)
generator: "portal-rs"
---

# BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 | BCDA Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. \[NASDAQ:BCDA\], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to: https://dpregister.com/sreg/10211154/104a4f51d2e.

Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ufQzaenK.

A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 12, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 3063624. 

**About BioCardia®**  
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart 3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biological therapies. For more information visit www.biocardia.com.

**MEDIA CONTACT:**  
Miranda Peto, Investor Relations  
mpeto@biocardia.com  
(650) 226-0120

**INVESTOR CONTACT:**  
David McClung, Chief Financial Officer  
investors@biocardia.com  
(650) 226-0120

### Related Stocks

- [BCDA.US](https://longbridge.com/en/quote/BCDA.US.md)

## Related News & Research

- [BioCardia receives Nasdaq notice for trading below $1 minimum bid price requirement](https://longbridge.com/en/news/296650912.md)
- [BioCardia Advances Helix Catheter Toward De Novo Approval](https://longbridge.com/en/news/296793880.md)
- [BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target](https://longbridge.com/en/news/296809944.md)
- [BioCardia CEO Peter Altman acquires 5,400 common shares worth $5,022](https://longbridge.com/en/news/296252378.md)
- [BioCardia Q2 net loss narrows on lower R&D costs](https://longbridge.com/en/news/295704552.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**